Jennifer Dong

1.4k total citations · 1 hit paper
27 papers, 1.1k citations indexed

About

Jennifer Dong is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Jennifer Dong has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Pharmacology and 10 papers in Oncology. Recurrent topics in Jennifer Dong's work include Pharmacogenetics and Drug Metabolism (10 papers), Drug Transport and Resistance Mechanisms (4 papers) and Fibroblast Growth Factor Research (3 papers). Jennifer Dong is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Drug Transport and Resistance Mechanisms (4 papers) and Fibroblast Growth Factor Research (3 papers). Jennifer Dong collaborates with scholars based in United States, Germany and United Kingdom. Jennifer Dong's co-authors include Roberto A. Calle, Veena Somayaji, J Chabot, Kathryn E. Gropp, Tim Rolph, Saswata Talukdar, Yan Weng, Michelle I. Rossulek, Philip C. Smith and Dongmei Li and has published in prestigious journals such as Diabetes Care, Cell Metabolism and The American Journal of Medicine.

In The Last Decade

Jennifer Dong

26 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

2016 406 citations Saswata Talukdar, Yingjiang Zhou et al. Cell Metabolism profile →

Peers

Jennifer Dong

ONCOL

PHYSI

EPIDE

RNMI

Toshifumi Ito Japan

Yi‐Jen Liao Taiwan

Chibo Liu China

Jonathan Vigne France

Xia Bai China

Guohong Zhao China

Thomas Schlüter Germany

Lucia Stefanini Italy

Keizo Kagawa Japan

Toshifumi Ito Japan

Jennifer Dong

653 ×1.0

280 ×1.8

ONCOL

91 ×0.6

PHYSI

168 ×1.2

EPIDE

94 ×0.9

RNMI

Citations per year, relative to Jennifer Dong Jennifer Dong (= 1×) peers Toshifumi Ito

Countries citing papers authored by Jennifer Dong

Since Specialization

Citations

This map shows the geographic impact of Jennifer Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Dong more than expected).

Fields of papers citing papers by Jennifer Dong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Dong. The network helps show where Jennifer Dong may publish in the future.

Co-authorship network of co-authors of Jennifer Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Dong. A scholar is included among the top collaborators of Jennifer Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Dong. Jennifer Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lü, Hong, Jatinder Kaur Mukker, Jayaprakasam Bolleddula, et al.. (2024). Asia‐inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler. Clinical and Translational Science. 17(10). e70050–e70050. 1 indexed citations

Gopalakrishnan, Sathej, Özkan Yalkinoglu, Hong Lü, et al.. (2024). Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial. Clinical Pharmacology & Therapeutics. 115(6). 1346–1357. 13 indexed citations

Dai, Haiqing, James S. Bourdage, Dongli Zhou, et al.. (2024). Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma. Clinical and Translational Science. 17(3). e13730–e13730. 4 indexed citations

Schieferstein, Hanno, Ralf Schmidt, Klaus Pusecker, et al.. (2023). Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective. Xenobiotica. 53(8-9). 547–558.

Nyberg, Joakim, Orestis Papasouliotis, Andreas Johne, et al.. (2022). Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations. Cancer Chemotherapy and Pharmacology. 90(1). 53–69. 8 indexed citations

Telli, Melinda L., Sara M. Tolaney, Geoffrey I. Shapiro, et al.. (2022). Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. npj Breast Cancer. 8(1). 45–45. 31 indexed citations

Vugmeyster, Yulia, George Locke, Christoph Helwig, et al.. (2022). Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach. Clinical and Translational Science. 15(12). 2838–2843. 2 indexed citations

Dyroff, Martin C., Andreas Port, Jennifer Dong, et al.. (2021). Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants. Clinical and Translational Science. 14(6). 2420–2430. 11 indexed citations

Plummer, Ruth, Emma Dean, Hendrik‐Tobias Arkenau, et al.. (2021). A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer. 163. 19–26. 26 indexed citations

10.

Dong, Jennifer, J Gosset, Odette A. Fahmi, et al.. (2017). Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome. Drug Metabolism and Disposition. 45(5). 501–511. 18 indexed citations

11.

Talukdar, Saswata, Yingjiang Zhou, Dongmei Li, et al.. (2016). A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Cell Metabolism. 23(3). 427–440. 406 indexed citations breakdown →

12.

Chen, Bin, et al.. (2012). Pharmacokinetics/Pharmacodynamics Model-Supported Early Drug Development. Current Pharmaceutical Biotechnology. 13(7). 1360–1375. 22 indexed citations

13.

Dong, Jennifer, David H. Salinger, Christopher J. Endres, et al.. (2011). Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies. Clinical Pharmacokinetics. 50(2). 131–142. 119 indexed citations

14.

Dong, Jennifer & Philip C. Smith. (2009). Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes. Drug Metabolism and Disposition. 37(12). 2314–2322. 23 indexed citations

15.

Gibbs, J. M., Jennifer Dong, Bin Chen, Megan Gibbs, & Maurice G. Emery. (2008). Applications of Computer-Aided Pharmacokinetic and Pharmacodynamic Methods from Drug Discovery Through Registration. Current Computer - Aided Drug Design. 4(1). 54–66. 10 indexed citations

16.

Dong, Jennifer, Jianhua Liu, & Philip C. Smith. (2005). Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo. Biochemical Pharmacology. 70(6). 937–948. 37 indexed citations

17.

Dong, Jennifer, Darius Babusis, Devin Welty, et al.. (2004). Effects of the Preservative Purite ^® on the Bioavailability of Brimonidine in the Aqueous Humor of Rabbits. Journal of Ocular Pharmacology and Therapeutics. 20(4). 285–292. 32 indexed citations

18.

Remick, Scot C., Madhumita Patnaik, Navid Ziran, et al.. (2000). Human herpesvirus-8–associated disseminated angiosarcoma in an HIV-seronegative woman: report of a case and limited case-control virologic study in vascular tumors. The American Journal of Medicine. 108(8). 660–664. 16 indexed citations

19.

Dong, Jennifer, et al.. (2000). Pharmacokinetics of Ibuprofen Enantiomers in Children with Cystic Fibrosis. The Journal of Clinical Pharmacology. 40(8). 861–868. 8 indexed citations

20.

Dong, Jennifer, Amy S. Etheridge, & Philip C. Smith. (1999). Effect of Selective Phase II Enzyme Inducers on Glucuronidation of Benoxaprofen in Rats. Drug Metabolism and Disposition. 27(12). 1423–1428. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact